Literature DB >> 29018052

Intratumoral HPV16-Specific T Cells Constitute a Type I-Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer.

Marij J P Welters1, Wenbo Ma1, Saskia J A M Santegoets1, Renske Goedemans1, Ilina Ehsan1, Ekaterina S Jordanova2, Vanessa J van Ham1, Vincent van Unen3, Frits Koning3, Sylvia I van Egmond4, Pornpimol Charoentong5, Zlatko Trajanoski5, Lilly-Ann van der Velden4, Sjoerd H van der Burg6.   

Abstract

Purpose: Human papillomavirus (HPV)-associated oropharyngeal squamous cell cancer (OPSCC) has a much better prognosis than HPV-negative OPSCC, and this is linked to dense tumor immune infiltration. As the viral antigens may trigger potent immunity, we studied the relationship between the presence of intratumoral HPV-specific T-cell responses, the immune contexture in the tumor microenvironment, and clinical outcome.Experimental Design: To this purpose, an in-depth analysis of tumor-infiltrating immune cells in a prospective cohort of 97 patients with HPV16-positive and HPV16-negative OPSCC was performed using functional T-cell assays, mass cytometry (CyTOF), flow cytometry, and fluorescent immunostaining of tumor tissues. Key findings were validated in a cohort of 75 patients with HPV16-positive OPSCC present in the publicly available The Cancer Genome Atlas database.
Results: In 64% of the HPV16-positive tumors, type I HPV16-specific T cells were present. Their presence was not only strongly related to a better overall survival, a smaller tumor size, and less lymph node metastases but also to a type I-oriented tumor microenvironment, including high numbers of activated CD161+ T cells, CD103+ tissue-resident T cells, dendritic cells (DC), and DC-like macrophages.Conclusions: The viral antigens trigger a tumor-specific T-cell response that shapes a favorable immune contexture for the response to standard therapy. Hence, reinforcement of HPV16-specific T-cell reactivity is expected to boost this process. Clin Cancer Res; 24(3); 634-47. ©2017 AACRSee related commentary by Laban and Hoffmann, p. 505. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29018052     DOI: 10.1158/1078-0432.CCR-17-2140

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  55 in total

1.  NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.

Authors:  Nadine van Montfoort; Linda Borst; Michael J Korrer; Marjolein Sluijter; Koen A Marijt; Saskia J Santegoets; Vanessa J van Ham; Ilina Ehsan; Pornpimol Charoentong; Pascale André; Nicolai Wagtmann; Marij J P Welters; Young J Kim; Sytse J Piersma; Sjoerd H van der Burg; Thorbald van Hall
Journal:  Cell       Date:  2018-11-29       Impact factor: 41.582

2.  Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial.

Authors:  Erminia Massarelli; William William; Faye Johnson; Merrill Kies; Renata Ferrarotto; Ming Guo; Lei Feng; J Jack Lee; Hai Tran; Young Uk Kim; Cara Haymaker; Chantale Bernatchez; Michael Curran; Tomas Zecchini Barrese; Jaime Rodriguez Canales; Ignacio Wistuba; Lerong Li; Jing Wang; Sjoerd H van der Burg; Cornelis J Melief; Bonnie Glisson
Journal:  JAMA Oncol       Date:  2019-01-01       Impact factor: 31.777

3.  Tissue-Specific Gene Expression during Productive Human Papillomavirus 16 Infection of Cervical, Foreskin, and Tonsil Epithelium.

Authors:  Sreejata Chatterjee; Sa Do Kang; Samina Alam; Anna C Salzberg; Janice Milici; Sjoerd H van der Burg; Willard Freeman; Craig Meyers
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

Review 4.  [Radiotherapeutic studies of head and neck cancer-highlights of the 2018 ASCO Annual Meeting].

Authors:  S Ott; T Wiegel; S Laban; T K Hoffmann; C Petersen; S Tribius
Journal:  HNO       Date:  2018-12       Impact factor: 1.284

5.  Immunometabolic Alterations by HPV Infection: New Dimensions to Head and Neck Cancer Disparity.

Authors:  Sanjib Chaudhary; Koelina Ganguly; Sakthivel Muniyan; Ramesh Pothuraju; Zafar Sayed; Dwight T Jones; Surinder K Batra; Muzafar A Macha
Journal:  J Natl Cancer Inst       Date:  2019-03-01       Impact factor: 13.506

Review 6.  Therapeutic cancer vaccines.

Authors:  Mansi Saxena; Sjoerd H van der Burg; Cornelis J M Melief; Nina Bhardwaj
Journal:  Nat Rev Cancer       Date:  2021-04-27       Impact factor: 60.716

7.  Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome.

Authors:  Véronique M Braud; Jérôme Biton; Etienne Becht; Samantha Knockaert; Audrey Mansuet-Lupo; Estelle Cosson; Diane Damotte; Marco Alifano; Pierre Validire; Fabienne Anjuère; Isabelle Cremer; Nicolas Girard; Dominique Gossot; Agathe Seguin-Givelet; Marie-Caroline Dieu-Nosjean; Claire Germain
Journal:  Oncoimmunology       Date:  2018-01-29       Impact factor: 8.110

8.  HPV Epitope Processing Differences Correlate with ERAP1 Allotype and Extent of CD8+ T-cell Tumor Infiltration in OPSCC.

Authors:  Emma Reeves; Oliver Wood; Christian H Ottensmeier; Emma V King; Gareth J Thomas; Tim Elliott; Edward James
Journal:  Cancer Immunol Res       Date:  2019-05-31       Impact factor: 11.151

Review 9.  [Comparison of T cell response in the tumor milieu of patients with HPV+ and HPV- head and neck cancer].

Authors:  T Bastian; S Lang; B A Kansy
Journal:  HNO       Date:  2020-02       Impact factor: 1.284

Review 10.  Local heroes or villains: tissue-resident memory T cells in human health and disease.

Authors:  S C Sasson; C L Gordon; S N Christo; P Klenerman; L K Mackay
Journal:  Cell Mol Immunol       Date:  2020-01-22       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.